{"id":"W4399071580","doi":"10.1200/jco.23.01462","title":"Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"National Cancer Institute; AstraZeneca","keywords":"Tremelimumab; Durvalumab; Medicine; Sorafenib; Hepatocellular carcinoma; Regimen; Internal medicine; Oncology; Surgery; Cancer; Immunotherapy; Nivolumab; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001889068,0.0004635551,0.00074691,0.0002220092,0.000427469,0.0005705443,0.0004000684,0.0003113633,0.001464486],"category_scores_gemma":[0.001089803,0.0001806517,0.0007305921,0.0004426706,0.0003065542,0.0002873449,0.0003529433,0.0008299312,0.000216952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005595741,"about_ca_system_score_gemma":0.0008313546,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001285446,"about_ca_topic_score_gemma":0.002419347,"domain_scores_codex":[0.999266,0.0004297057,0.00004339452,0.00005837811,0.0001404635,0.00006212404],"domain_scores_gemma":[0.9986684,0.0002000773,0.0005247089,0.0001226597,0.0001340422,0.000350144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4854027,0.01477191,0.4006473,0.002258057,0.01231726,0.0003639782,0.0007500263,0.002411642,0.01080441,0.0002268226,0.004043047,0.06600282],"study_design_scores_gemma":[0.1009622,0.0599308,0.8252625,0.0001067365,0.004879908,0.0005388972,0.0002515206,0.001299266,0.003615689,0.0001339909,0.002950561,0.00006793552],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965889,0.0009254756,0.0001064667,0.00007256404,0.00001401098,0.0003676974,0.001217612,0.000005993239,0.0007012704],"genre_scores_gemma":[0.9968719,0.000402348,0.000193192,0.00009175523,0.00003006968,0.0003917517,0.001664098,0.000001892481,0.000353119],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001889068,"threshold_uncertainty_score":0.009990454,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.227431192539415,"score_gpt":0.4282499582866636,"score_spread":0.2008187657472487,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}